Droxidopa

(Northera®)

Droxidopa

Drug updated on 12/11/2024

Dosage FormCapsules (oral: 100 mg, 200 mg, 300 mg)
Drug ClassSympathomimetics
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of orthostatic dizziness and light-headedness or the feeling that you are about to black out in adult patients with symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure (Parkinson's disease [PD], multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • This summary is based on the review of one systematic review/meta-analysis. [1]
  • Pharmacologic treatments, including droxidopa, midodrine, ivabradine, bisoprolol, fludrocortisone, desmopressin, propranolol, modafinil, methylphenidate, and melatonin, were effective in reducing postural orthostatic tachycardia syndrome (POTS) symptoms and improving orthostatic tolerance.
  • Effectiveness outcomes across the drugs were comparable, with each showing positive impacts on reducing POTS symptoms and enhancing patients’ ability to tolerate orthostasis.
  • There is no safety information available in the reviewed studies.
  • There is no population types or subgroups information available in the reviewed studies.

Product Monograph / Prescribing Information

Document TitleYearSource
Northera (droxidopa) Prescribing Information.2019Lundbeck, Deerfield, IL

Systematic Reviews / Meta-Analyses